Anti‐N‐glycolylneuraminic acid antibodies identified in healthy human serum

A Zhu, R Hurst - Xenotransplantation, 2002 - Wiley Online Library
A Zhu, R Hurst
Xenotransplantation, 2002Wiley Online Library
The first and major clinical obstacle in xenotransplantation is antibody‐mediated hyperacute
rejection. Although human natural antibodies against Galα1, 3Gal (Gal) antigens, which are
common on porcine cells and organs, have been identified to play a major role in
hyperacute rejection, other natural antibodies against non‐Gal epitopes may be also
involved in the process. Here, we present evidence suggesting that the majority of human
anti‐non‐Gal antibodies are specific for carbohydrate structures carrying terminally linked N …
Abstract: The first and major clinical obstacle in xenotransplantation is antibody‐mediated hyperacute rejection. Although human natural antibodies against Galα1,3Gal (Gal) antigens, which are common on porcine cells and organs, have been identified to play a major role in hyperacute rejection, other natural antibodies against non‐Gal epitopes may be also involved in the process. Here, we present evidence suggesting that the majority of human anti‐non‐Gal antibodies are specific for carbohydrate structures carrying terminally linked N‐glycolylneuraminic acid (NeuGc), a xenoantigen existing in almost all animals except humans. Furthermore, this anti‐NeuGc activity is detectable in 85% of healthy humans, implicating the involvement of NeuGc in hyperacute rejection and the importance of developing strategies for removing NeuGc for clinical xenotransplantation.
Wiley Online Library